S100A1 proteins for treatment and prevention of infarct extension
By using S100A1 protein and its related nucleic acids and vectors, the problem of infarction prolongation after myocardial infarction is solved, effective prevention and treatment of infarction prolongation is achieved, and cardiac function is protected.
CN119698287APending Publication Date: 2025-03-25帕特里克·莫斯特 +2
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202380044482.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-02
- Filing Date
- 2023-06-01
- Publication Date
- 2025-03-25
AI Technical Summary
Technical Problem
The prior art lacks effective methods to prevent or treat infarction prolongation after myocardial infarction, resulting in collateral damage to the non-infarct myocardium.
Method used
Treatment and/or prevention of infarction prolongation is performed on patients in need by using S100A1 protein, biologically active fragments or variants thereof, or nucleic acids encoding these proteins, in combination with carriers and pharmaceutical compositions.
Benefits of technology
This method can effectively inhibit the inflammatory response after myocardial infarction, weaken the activity of the immune system, thereby limiting the extension of infarction, protecting the non-infarction myocardium, and improving cardiac function.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to an S100A1 protein, a bioactive fragment thereof or a variant thereof, a nucleic acid encoding the S100A1 protein or the bioactive fragment thereof or the variant thereof, a carrier comprising the nucleic acid, and a pharmaceutical composition comprising the protein or the bioactive fragment thereof or the variant thereof, the nucleic acid and / or the carrier, it is useful for treating and / or preventing infarction extension in a patient in need thereof.
Need to check novelty before this filing date? Find Prior Art